



## **Crescendo Biologics' James Legg to Present at 4th Annual Crown Bioscience Cambridge Symposium, 15 March 2018**

**Cambridge, UK, 9 March 2018** – Crescendo Biologics Limited (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, announces that James Legg, VP R&D, will be presenting at the 4th Annual Crown Bioscience Cambridge Symposium on 15 March 2018.

The 4th Annual Crown Bioscience Cambridge Symposium is being held at the Babraham Research Campus on 15 March. This year, the symposium will focus on immuno-oncology and the future advances in cancer treatment, with the symposium entitled '*Perspectives on Oncology Drug Discovery: Immuno-Oncology and the Next Generation*'. Discussion topics will include how to assess long term anti-tumour immunotherapeutic efficacy, novel targets for next generation immuno-oncology agents, as well as preclinical models for improved evaluation of immuno-therapeutics.

**Title:** Perspectives on Oncology Drug Discovery: Immuno-Oncology and the Next Generation

**Date:** 15 March 2018

**Time:** Whole day event

**Location:** The Cambridge Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT

**Ends**

**For more information, please contact:**

<b>Crescendo Biologics</b> Dr Peter Pack, CEO	<b>Tel: 44 (0)1223 497140</b> <a href="mailto:info@crescendobiologics.com">info@crescendobiologics.com</a>
<b>Instinctif Partners</b> Deborah Bell / Dr Christelle Kerouedan / Melanie Toyne-Sewell	<b>Tel: 44 (0)20 7457 2020</b> <a href="mailto:crescendo@instinctif.com">crescendo@instinctif.com</a>

### **Notes to Editors:**

#### **About Crescendo Biologics Ltd**

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody® therapeutics in oncology, with an internal focus on biologics for Targeted T-cell Therapy with novel modes-of-action. It is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, in both multi- functional immuno-oncology modulators and Humabody® Drug Conjugates (HDCs), the next generation of ADCs.

The Company's Humabody® therapeutics are based on its unique, patent protected, transgenic mouse



platform, generating 100% human V<sub>H</sub> domain building blocks (Humabody® V<sub>H</sub>) comprising the full structural diversity of the human V<sub>H</sub> repertoire and superior biophysical properties as a result of their in vivo maturation.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: [www.crescendobiologics.com](http://www.crescendobiologics.com)